QA PharmaPro Consulting

Request an Assessment

Author: QA PharmaPro Consulting

  • What Regulated Customers Expect Before Trusting a GxP SaaS Platform

    DIGITAL COMPLIANCE

    A regulated customer is not buying software alone. It is deciding whether the platform, the supplier and the available evidence can support a controlled GxP process.

    That distinction changes the sales conversation. Claims such as “validated,” “Part 11 compliant” or “built for life sciences” may attract attention, but they do not answer the questions a Quality, Regulatory, IT or business owner must resolve before approving a system for regulated use.

    The decisive question is not whether a SaaS product has compliance features. It is whether the customer can define its intended use, understand the risks, configure the system appropriately, obtain proportionate assurance and maintain control throughout the lifecycle.

    1. A clear intended use and regulated boundary

    Before assessing features, the customer needs to know what the platform will do in its own process. Will it create, modify, approve, retain or transmit regulated records? Will it support a quality decision? Could a failure affect product quality, patient safety, data integrity or regulatory evidence?

    The same platform can have different risk profiles in different implementations. A tool used for informal collaboration is not equivalent to the same tool used to approve deviations, manage training records or control manufacturing data. A credible supplier helps the customer define that boundary instead of making a blanket compliance claim.

    2. A defensible allocation of responsibilities

    In SaaS, control is shared. The supplier controls the underlying product, infrastructure, release process and many security safeguards. The customer controls intended use, configuration choices, user access, procedures, training and the decision to release the system for use.

    Regulated customers therefore expect a responsibility model that makes this division explicit. They need to understand who performs testing, reviews audit trails, approves changes, manages incidents, retains records, verifies backups and evaluates new releases. Ambiguity here becomes a validation gap later.

    3. Evidence that supports risk-based assurance

    The evidence package should help the customer reach a justified conclusion without recreating the supplier’s entire development lifecycle. Useful evidence commonly includes:

    • a current system description, architecture and data-flow overview;
    • documented software development and quality practices;
    • requirements or feature specifications traceable to testing;
    • release notes and a controlled change-management process;
    • security, availability, backup and recovery information;
    • incident, problem and vulnerability-management processes;
    • evidence for configurable controls such as access, audit trails and electronic signatures;
    • data export, retention and termination provisions;
    • independent certifications or reports, where relevant, with their scope clearly stated.

    More documentation is not automatically better. The objective is sufficient evidence for the actual risks and intended use. FDA’s final Computer Software Assurance guidance encourages a risk-based approach for production and quality-management-system software used in medical device manufacturing. Its scope matters: it should not be represented as a universal rule for every GxP application. Its underlying discipline, however—focus assurance effort on the functions and failures that matter—is highly relevant to sound validation strategy.

    4. Controls that work in the customer’s configuration

    A feature list is not proof of effective control. The customer needs to evaluate how controls behave in the proposed configuration and business process.

    • Access: Can privileges be limited by role and reviewed over time?
    • Audit trails: Are relevant actions captured, time-stamped, retained and available for meaningful review?
    • Records: Can complete, accurate and readable copies be produced throughout the retention period?
    • Electronic signatures: Where signatures are used, are identity, intent and record linkage appropriately controlled?
    • Data integrity: Are changes attributable, original information preserved and exceptions detectable?
    • Workflow: Does the configuration enforce required sequencing, review and approval steps?

    For FDA-regulated electronic records and signatures, the applicable requirements are set out in 21 CFR Part 11. In the EU GMP context, EudraLex Volume 4, Annex 11 addresses computerized systems. Applicability depends on the regulated process, record and jurisdiction; it cannot be established by marketing language alone.

    5. Lifecycle control after go-live

    Initial validation is only the beginning. SaaS products evolve continuously, while regulated customers must maintain a controlled state. Customers will look for advance notice of material changes, meaningful release information, a way to assess impact before deployment, and clear handling of emergency fixes.

    The strongest operating model distinguishes changes that require customer assessment from changes that do not affect regulated use. It also defines periodic review, user-access review, audit-trail review where appropriate, incident escalation, supplier performance monitoring and business-continuity testing.

    6. Transparency about limitations

    Trust increases when a supplier states what the platform does not control. A defensible position may say that the product provides technical capabilities supporting Part 11 or Annex 11 requirements, while the customer remains responsible for determining applicability, validating its intended use and operating the system under controlled procedures.

    This is stronger than declaring the platform “compliant” in isolation. Compliance is achieved through the combined system of technology, configuration, people, procedures and evidence.

    Questions regulated buyers will ask

    • Which GxP processes and records will this system support?
    • What failures could affect product quality, patient safety, data integrity or a regulatory decision?
    • What assurance has the supplier performed, and what evidence is available to customers?
    • Which controls are standard, configurable or dependent on customer procedures?
    • How are releases, incidents and security vulnerabilities communicated?
    • Can records and audit trails be exported in usable form and retained for the required period?
    • What happens to data and evidence if the service ends?
    • If AI-enabled functions are used, how are intended use, human oversight, changes and output risks controlled?

    The commercial advantage of being assessment-ready

    A supplier that can answer these questions early shortens diligence, reduces repetitive questionnaires and gives regulated buyers a clearer path to approval. The goal is not to promise zero risk. It is to show that risks are understood, responsibilities are defined and the evidence supports the claims being made.

    For SaaS companies entering life-science markets, the right starting point is a gap assessment of the product, evidence package, supplier controls and customer-facing claims. For regulated companies selecting a platform, it is an intended-use and risk assessment that determines what must be verified before approval.

    Need a defensible GxP SaaS validation strategy?

    QA PharmaPro assesses intended use, validation evidence, Part 11 and Annex 11 controls, supplier oversight and lifecycle risks—then translates the gaps into a practical action plan.

    Request a Confidential Assessment

    Explore our GxP digital systems, CSA and Part 11 consulting, see the industries we support in GxP SaaS & Digital Systems, or review our consulting case studies.

  • The Regulatory Path Is a Business Decision Before It Is a Submission Decision

    BEYOND COMPLIANCE

    The Regulatory Path Is a Business Decision Before It Is a Submission Decision

    A regulatory pathway is often treated as a technical classification exercise. In practice, it can determine evidence burden, supplier responsibilities, claims flexibility, launch timing, cost and the commercial model itself.

    That means the right question is not simply, “Which route can we file?” The stronger question is, “Which route can our evidence, product strategy and operating model actually defend?”

    The Expensive Mistake Happens Before the Submission

    By the time a submission package is assembled, many business assumptions may already be locked: intended use, product claims, supplier contracts, labeling, development scope, validation expectations and launch commitments. If the pathway decision was weak, the rework is no longer just regulatory. It becomes operational and commercial.

    A Defensible Pathway Must Survive Three Tests

    • Regulatory fit: classification, intended use, claims and applicable requirements are coherent.
    • Evidence fit: the available and planned evidence can support the route without filling critical gaps with assumptions.
    • Business fit: the route is compatible with timing, supplier structure, commercial claims, resources and downstream obligations.

    A route that passes only the first test may still be the wrong route for the business.

    Make the Decision While It Is Still Cheap to Change

    The best time to challenge the pathway is before evidence generation, supplier commitments and commercial promises make the decision expensive to reverse. A focused regulatory assessment should expose the assumptions, identify the evidence that matters and clarify the consequences of each viable route.

    QA PharmaPro perspective: The strongest regulatory strategy is not the most aggressive or the most conservative. It is the route the available evidence and business model can defend without creating avoidable downstream risk.

    Request a Confidential Assessment

  • A Plausible Regulatory Answer Is Not Necessarily a Defensible One

    Regulatory and Quality decisions often fail for a simple reason: the conclusion sounds reasonable, so the organization stops asking whether the evidence is actually strong enough to support it.

    That distinction matters. A plausible interpretation may still rely on assumptions, missing records, weak traceability, unsupported claims or an incomplete understanding of the applicable requirement.

    Evidence Has to Carry the Conclusion

    A defensible answer connects the decision to the applicable framework, the available evidence, the known limitations and the remaining uncertainty. It explains not only what the organization concluded, but why that conclusion was reasonable at the time it was made.

    The Dangerous Gap Is the Unsupported Assumption

    When evidence is incomplete, teams naturally fill the gap with experience, precedent or what appears to be the most likely interpretation. Sometimes that is appropriate. The mistake is allowing the assumption to become invisible.

    Strong regulated decision-making makes uncertainty explicit. It separates what is known from what is inferred and identifies what additional evidence is necessary before the business commits to the next step.

    The Better Review Question

    Do not ask only, “Does this answer make sense?” Ask: “If a regulator, auditor, customer or notified body challenged this conclusion, what evidence would we put on the table?”

    That question changes the quality of the decision before the challenge arrives.

    Need an independent view? We test whether the conclusion is actually supported by the evidence and identify the gaps that could become regulatory, audit or commercial risk.

    Request a Confidential Assessment

  • The Expensive Time to Build Quality Is After Your Evidence Is Already Locked

    Quality work is often treated as something that can be added once the product, system or commercial plan is mostly settled. That is usually when it becomes most expensive.

    By that point, the organization may already have generated development evidence, selected suppliers, configured a digital system, defined claims, committed to a launch date or promised a customer that the product is ready. The Quality function is then asked to make the existing evidence support a decision it was never designed to defend.

    The Cost Is Not the SOP

    The real cost is rework: repeating validation, redesigning documentation, changing claims, rebuilding traceability, requalifying suppliers or delaying market entry because a critical assumption was not tested early enough.

    Quality Should Enter Before the Evidence Is Frozen

    The highest-value Quality work often happens before a major commitment. At that stage, the organization can still ask the useful questions: What decision must this evidence support? What would an auditor, regulator or enterprise customer expect to see? Which assumptions are material? Which controls are proportionate to the risk?

    That does not mean adding bureaucracy earlier. It means making the evidence strategy deliberate before change becomes expensive.

    The Practical Test

    Before the next business milestone, ask one question: if this decision were challenged tomorrow, could the available evidence explain and defend why the organization moved forward?

    If the answer is unclear, the Quality problem already exists — even if the documentation looks complete.

    Need this applied to your evidence? A confidential assessment tests whether the current Quality and Regulatory position can support the next business milestone before rework becomes expensive.

    Request a Confidential Assessment